Estrella Immunopharma, Inc.

Nasdaq:ESLANasdaq:ESLAW

Biological Products, (No Diagnostic Substances)·EMERYVILLE, CA

CEO

Liu Cheng

CFO

Xu Jiandong

Financials

17 shown

Type	Period	Ended	Filed
10-Q	Q3 2025	9/30/25	11/12/25	→
10-Q	Q2 2025	6/30/25	8/12/25	→
10-Q	Q1 2025	3/31/25	5/14/25	→
10-Q	Q3 2024	9/30/24	11/14/24	→
10-K/A	FY 2024	6/30/24	10/28/24	→
10-K	FY 2024	6/30/24	9/27/24	→
↓

News (8-K)

60 shown

Filed	Type	Description
1/13/26	Delisting	CURREN REPORT	→
1/6/26	Agreement	Entry into a Material Definitive Agreement	→
12/4/25	Other	Other Events	→
11/6/25	Other	Other Events	→
9/29/25	Other	Other Events	→
9/26/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
2/13/26	424B3	424B3	→
1/22/26	S-1/A	REGISTRATION STATEMENT	→
1/16/26	S-1/A	REGISTRATION STATEMENT	→
1/6/26	424B5	PROSPECTUS SUPPLEMENT	→
12/22/25	S-1	REGISTRATION STATEMENT	→
12/23/24	S-8	REGISTRATION STATEMENT	→
↓

Filing History(239 filings)

TypeDateAccessionPeriodSize

424B3

Feb 13, 2026

0001213900-26-016605PROSPECTUS

—

6.4 MB

EFFECT

Jan 23, 2026

9999999995-26-000279

—

1.8 KB

S-1/A

Jan 22, 2026

0001213900-26-006410REGISTRATION STATEMENT

—

277.5 KB

S-1/A

Jan 16, 2026

0001213900-26-005233REGISTRATION STATEMENT

—

17.2 MB

8-K

Jan 13, 2026

0001213900-26-003998CURREN REPORT

Jan 7, 2026

235.7 KB

8-K

Jan 6, 2026

0001213900-26-001777CURRENT REPORT

Jan 5, 2026

1.1 MB

424B5

Jan 6, 2026

0001213900-26-001686PROSPECTUS SUPPLEMENT

—

348.0 KB

S-1

Dec 22, 2025

0001213900-25-124247REGISTRATION STATEMENT

—

15.2 MB

8-K

Dec 4, 2025

0001213900-25-118097CURRENT REPORT

Dec 4, 2025

255.2 KB

10-Q

Nov 12, 2025

0001213900-25-109198QUARTERLY REPORT

Sep 30, 2025

4.1 MB

8-K

Nov 6, 2025

0001213900-25-107249CURRENT REPORT

Nov 3, 2025

255.1 KB

Oct 1, 2025

0001213900-25-094562

Sep 22, 2025

3.0 KB

8-K

Sep 29, 2025

0001213900-25-093197CURRENT REPORT

Sep 23, 2025

237.2 KB

8-K

Sep 26, 2025

0001213900-25-092471CURRENT REPORT

Sep 22, 2025

237.6 KB

10-Q

Aug 12, 2025

0001213900-25-074567QUARTERLY REPORT

Jun 30, 2025

4.0 MB

8-K

Aug 7, 2025

0001213900-25-072746CURRENT REPORT

Aug 1, 2025

239.6 KB

8-K

Jun 5, 2025

0001213900-25-051361CURRENT REPORT

Jun 5, 2025

249.9 KB

8-K

Jun 3, 2025

0001213900-25-050329CURRENT REPORT

May 30, 2025

416.4 KB

8-K

May 29, 2025

0001213900-25-048597CURRENT REPORT

May 29, 2025

256.2 KB

10-Q

May 14, 2025

0001213900-25-043365QUARTERLY REPORT

Mar 31, 2025

3.7 MB

8-K

May 2, 2025

0001213900-25-039261FORM 8-K

Apr 30, 2025

245.4 KB

10-KT

Mar 25, 2025

0001013762-25-002190TRANSITION REPORT

Dec 31, 2024

11.2 MB

8-K

Feb 21, 2025

0001213900-25-015851CURRRENT REPORT

Feb 21, 2025

257.3 KB

8-K

Feb 20, 2025

0001213900-25-015364FORM 8-K

Feb 19, 2025

260.9 KB

Feb 14, 2025

0001213900-25-014310

Oct 30, 2024

8.6 KB

25 filings shown

Filed	Form	Description
7/26/23	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
7/12/23	DEFA14A	DEFA14A	→
6/16/23	DEF 14A	DEF 14A	→
5/25/23	PRE 14A	PRE 14A	→
12/6/22	DEF 14A	DEF 14A	→
11/25/22	PRE 14A	PRE 14A	→

Estrella Immunopharma, Inc.

Financials

News (8-K)

Prospectuses & Registrations

Filing History(239 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
10/1/25	3	3	→
2/14/25	4	4	→
2/14/25	4	4	→
8/23/24	3	3	→
10/30/23	SC 13D	SCHEDULE 13D	→
10/10/23	3	3	→
↓

Filed	Form	Description
1/23/26	EFFECT	EFFECT	→
12/19/24	EFFECT	EFFECT	→
12/28/23	EFFECT	EFFECT	→
10/5/23	25-NSE	25-NSE	→
9/20/23	425	425	→
9/18/23	425	425	→
↓